Search Results for "Arthritis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Arthritis. Results 41 to 50 of 142 total matches.
Lyme Disease Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999 (Issue 1049)
develop frank arthritis; a few of these develop chronic
arthritis that may be resistant to antibiotic ...
The first human vaccine for prevention of Lyme disease (LYMErix), has been approved by the FDA for use in patients 15 to 70 years old.
Hyaluronan Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998 (Issue 1030)
et al, J Rheumatol, 22:1311, 1995). Pseudogout arthritis,
caused by deposition of calcium ...
Sodium hyaluronate (Hyalgan - Sanofi) and hylan G-F 20 (Synvisc - Wyeth- Ayerst) have been approved by the FDA for intra-articular injections in patients with knee pain due to osteoarthritis. Hylan G-F 20 is a cross-linked derivative of hyaluronic acid with a higher molecular weight than sodium hyaluronate. 'Hyaluronan' refers to either the acid or its salt.
Tocilizumab (Actemra) for Giant Cell Arteritis
The Medical Letter on Drugs and Therapeutics • Sep 25, 2017 (Issue 1530)
. Tocilizumab ia also approved for
treatment of rheumatoid arthritis, polyarticular or
systemic juvenile ...
The FDA has approved the interleukin-6 (IL-6) receptor
antagonist tocilizumab (Actemra – Genentech) for
subcutaneous (SC) treatment of giant cell arteritis
in adults. It is the first drug to be approved in the US
for this indication. Tocilizumab is also approved for
treatment of rheumatoid arthritis, polyarticular or
systemic juvenile idiopathic arthritis, and cytokine
release syndrome.
Intra-Articular Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006 (Issue 1231)
effective in the
treatment of crystalline arthritis (such as gout and
pseudogout) and immune-mediated ...
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Efalizumab (Raptiva) for Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Dec 08, 2003 (Issue 1171)
arthritis, is also FDA-approved for treatment of psoriatic arthritis and may soon be
approved for psoriasis ...
Efalizumab (Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
; it was previously approved for treatment of
rheumatoid arthritis.1
THE DISEASE — PMR is an inflammatory rheumatic ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
Nabumetone - A New Nsaid
The Medical Letter on Drugs and Therapeutics • Apr 17, 1992 (Issue 868)
of rheumatoid
arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987 ...
Nabumetone (Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
) can prevent paradoxical arthritis flares.
Pegloticase can be used for prevention of gout flares ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Cardiovascular Safety of Cox-2 Inhibitors
The Medical Letter on Drugs and Therapeutics • Nov 12, 2001 (Issue 1118)
), for treatment of arthritis has been accompanied by concerns that
they may increase the risk of thrombotic ...
Related Articles Since Publication
Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex), both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of thrombotic cardiovascular events.
Antibacterial Drugs for Lyme Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
symptoms. Late disease, which usually presents as
arthritis, typically of the knee, neurologic symptoms ...
Lyme disease in the US is caused by the spirochete
Borrelia burgdorferi, which is transmitted to humans
by Ixodes scapularis (blacklegged [deer] tick) and
I. pacificus (western blacklegged tick). Most cases of
Lyme disease occur in late spring and early summer
in northeastern and mid-Atlantic states, the upper
Midwest, and in northern California. B. mayonii, which
is also transmitted by I. scapularis, has been shown to
cause a similar illness in the upper Midwest.